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Valorization
Background and target groups of portal dosimetry
Cancer is one of the main causes of death worldwide. Radiotherapy is one of the three treat-
ment modalities available (i.e. Surgery, chemotherapy, radiotherapy) and radiotherapy is ap-
plied in approximately 50% of all cancer patients. In-treatment dose verification of radio-
therapy is essential to assure treatment quality and document the treatment delivery and it
facilitates adaptive radiotherapy.
The main aim of radiotherapy is to deliver the planned or desired dose. During the course
of treatment there are many potential uncertainties and causes of dose differences. The un-
certainties and causes can be subdivided in four categories: 1) Errors in data transfer to the
treatment equipment; 2) Errors caused by technical failures of the treatment machine (i.e.
stuck MLC leaf); 3) Inaccuracies during the treatment planning process and, 4) Patient setup
and geometry changes. Accurate dose delivery is essential because a small difference in dose
of approximately 5% to the target can modify treatment outcome or increase the risk to severe
side effects drastically.
Dosimetry and especially in-treatment dosimetry is a method for verifying the treatment
quality in a quantitative way. While pre-treatment or plan quality assurancemanymethods ex-
ist to verify treatments, for in-treatment verification especially of highly dynamic treatments
the methods are much more limited. For in-treatment dosimetry several detectors can be
used: 1)Thermoluminescent dosimeters (TLDs); 2) Optically stimulated luminescent dosime-
ters (OSLDs); 3) Radiophotoluminescent dosimeters (RPLDs); 3) Film-radiographic and ra-
diochromic; 4) Metal-oxide semiconductor field effect transistors (MOSFETs); 5) Plastic scin-
tillation detectors, and 6) Electronic portal imaging devices (EPIDs). The disadvantage of
most detectors (i.e. TLD, OSLD, RPLD and MOSFET) is that only point doses can be mea-
sured while film and EPID dosimetry can measure a planar dose. Another disadvantage of
many detectors is that the can only be analysed after the treatment (i.e. TLD, OSLD, RPLD
and film). The EPID however has been shown capable of acting as a planar dosimeter that
can measure the dose during the treatment itself and can be both analysed during the actual
delivery and after the treatment. Portal dosimetry has the advantage that besides planar portal
dosimetry other methods have been developed for in-treatment dose verification to 3D portal
dosimetry and time-resolved portal dosimetry. These methods have been developed at out
institute.
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In-treatment portal dosimetry is gaining interest and is even mandatory to apply in sev-
eral countries across Europe (i.e. Denmark, France and the United Kingdom) due to serious
radiotherapy accidents. Although these accidents are rare and radiotherapy is one of the safest
cancer treatments, in-treatment dose verification not only verifies technically accurate delivery
but also verifies relevant patient related changes that can be captured and acted upon. Portal
dosimetry can be used to assure treatment quality, document the treatment delivery and facil-
itates adaptive radiotherapy. In this thesis we have shown that portal dosimetry is a valuable
method especially for radiotherapy and is essential for the treatment quality. Portal dosimetry
reaches it highest potential when applied to patients with a high risk of anatomical changes
throughout the delivery of the treatment. While each patient could benefit from in-treatment
portal dosimetry, this technique can be applied on most linear accelerators because the EPID
is installed on nearly everymachine. Both the large number of patients benefitting from portal
dosimetry and the high availability of EPIDs in radiotherapy departments creates a large basis
for a commercial solution of portal dosimetry to be integrated in the daily clinical practice of
the radiotherapy departments, as is mandatory in several European countries.
Background and target groups of portal dosimetry
To successfully commercialize portal dosimetry with the current absolute dose under full-
scatter conditions measured with the EPID a complete integration in the clinical radiotherapy
workflow is necessary. The the algorithms, methods and knowledge used and developed for
2D portal dosimetry at our institute have been licensed to one of the largest equipment sup-
pliers in radiotherapy (VARIAN Medical Systems) and some methods have been patented in
collaboration with the same company.
Furthermore, gross dose delivery errors should be capturedwith an ”on-line” or ”real-time”
dose delivery verification method based on time-resolved portal dosimetry methods. While
for the subtler dose delivery differences planar portal dosimetry (both time-integrated as time-
resolved) and 3D portal dosimetry results should be automatically generated and analysed
for ”off-line” presentation and review. However, to minimize clinical workload the ”off-line”
review of presented portal dosimetry results automated methods should be created to select
treatments to present to the end-user to review while the remaining treatments should be
automatically archived in the patient electronic medical record for treatment documentation
purposes. Decision criteria to trigger alerts and actions are therefore necessary to optimize
large scale clinical applicability.
Besides a portal dosimetry product that can be used with any linear accelerator the re-
quired knowledge of reviewing and analysing is essential for the decision-making for adaptive
radiotherapy. This ”expert” knowledge and the analysis of portal dosimetry methods can be
commercialized as a service to radiotherapy departments to improve their clinical guidelines
and protocols when using portal dosimetry.
Besides a portal dosimetry solution and ”expert” knowledge consultancy, the main hy-
pothesis of this thesis is that portal dosimetry information acquired in-treatment is useful for
informed decision making for adaptive radiotherapy. This was definitely shown, but needs to
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be further explored in the next few years. The aim of such an exploration is to define adap-
tive radiotherapy decision protocols. The protocols should standardize treatment adaption
decision to improve treatment accuracy. The improved treatment accuracy should minimize
side-effects and optimize local tumour control.
Innovation in comparison to other products in the market
Currently most solutions offered to apply patient specific plan quality assurance are applied
with specialized hardware. Solutions like the octavius (PTW, Freiburg, Germany), Matrixx
(IBA, Schwarzenbruck, Germany), Delta4 (Scandidos, Uppsala, Sweden), MapCHECK (Sun
Nuclear, Melbourne, United States) only offer pre-treatment patient specific quality assurance.
Usage of these hardware solutions is also time-consuming because inmost cases the device and
phantom has to be set-up in the treatment room before the measurement. Next to this a spe-
cial quality assurance plan needs to be created to compare measured versus predicted dose.
This occurs in many cases in the treatment planning system and this is exported in order to
be able to compare results in specialized software. Creating a special quality assurance plan is
not necessary when using pre-treatment quality assurance with the portal dosimeter and no
special phantoms need to be set-up for the measurement. Portal dosimetry therefore can be a
fast and accurate substitute to these dedicated devices for patient specific plan quality assur-
ance. Besides the pre-treatment portal dosimetry, it has been shown that portal dosimetry is
as an adequate procedure for in-treatment dose verification. Portal pre-treatment dosimetry is
already commercially available and supplied bymultiple different vendors. The solutions from
Varianmedical systems (PortalVision), EPIdos (EPIQA) and Standard Imaging /MathResolu-
tions (DosimetryCHECK) only offer patient specific plan quality assurance or pre-treatment
portal dosimetry. The only portal dosimetry solution also able to apply in-treatment portal
dosimetry is the solution from DOSIsoft (EPIgray).
Table 1 shows an overview of the solutions currently commercialy available and our so-
lution. It should be noted that many of the algorithms, methods and knowledge used and
developed at our institute have been licensed to one of the largest equipment suppliers in ra-
diotherapy and some methods have been patented in collaboration with the same company.
The time-resolved portal dosimetry methods developed at our institute received a prestigious
international award (Jack Fowler award, ESTRO). One of the major advantages of the meth-
ods developed at our institute is that it is based on absolute portal dosimetry. The methods
are developed for each type of verification from integrated planar portal dosimetry to time-
resolved 4D portal dosimetry. Next to this the methods can be modularly used for each type
of photon-based treatment modality from 3D CRT to FFF beam VMAT treatments. None of
the commercially available solutions offer this completeness with the different types of verifi-
cations possibilities.
129
Novel in-treatment dose verification methods for adaptive radiotherapy
Table 1: The different commercially available solutions in compared to each other.
Product Hardwaresolutions
Radiographic
film
Commercial
portal dosimetry
MAASTRO
portal dosimetry
1) Delta4 EBT3 1) PortalVision
2) Octavius 2) EPIGray
3) Matrixx 3) EPIDos
4) MapCHECK 4) Dosime-
tryCHECK
Company(s) 1) Scandidos Gafchromic 1) Varian Medical
Systems
2) PTW 2) Dosisoft
3) IBA 3) EPIQA
4) Sun Nuclear 4) Standard
Imaging / Math
Resolutions
Detector 1) Ionization
chamber
Film EPID EPID
2) Ionization
chamber
3) Ionization
chamber
4) Diodes
Pre-treatment 2D-3D 2D 2D-3D 2D-3D time
integrated and
time-resolved
In-treatment No Yes Yes, EPIGray only Yes
Measurement
time
(pre-treatment
/ in-treatment)
- / N/A +/- / +/- + / + (EPIGray) ++ / ++ (fully
automated)
Accuracy ++ ++ + / - +
Cost +/ - - ++ ++
Planning and realization of portal dosimetry to daily clinical practice
The used methods for integrated planar and 3D portal dosimetry will be integrated in a com-
mercial solution to be released in the next 2 to 4 years and can be used in clinics across the
world. For the time-resolved methods used in this thesis the methods are already patented
(Patent No: 14/074,144 pending) by the same company andMaastro Clinic and these methods
might become available after a successful introduction of the current time-integrated transit
planar dosimetry and time-integrated 3D portal dosimetry solution. This means that time-
resolved portal dosimetry will be available within the next decade.
Besides the development of more accurate models and other technical innovations, clin-
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ical decision protocols for adaptive radiotherapy should be developed now. These decision
protocols should eventually result in national and international guidelines to accurate and ad-
equate use of portal dosimetry in daily clinical practice. At this moment for an European
research project ARTFORCE (ClinicalTrials.gov Identifier: NCT01504815) the portal dosime-
try solution is implemented by us in several different sites across Europe. One of the aims of
this project is to investigate the predictive power of portal dosimetry and the added benefit in
daily clinical practice for adaptive radiotherapy. Next to this portal dosimetry is used within
this trial to document the actual treatment delivery. While the ARTFORCE trial documents
the treatment and defines decision protocols based on daily in-treatment measurements also
in silico studies or trials should be performed. The in silico studies or trials should investi-
gate in a controlled environment the behaviour and sensitivity and specificity of the different
in-treatment portal dosimetry methods which can be used. The in silico results can then be
validated in a trial like the ARTFORCE study. The knowledge acquired by the in silico trials
and portal dosimetry in general could be commercialized as a service for training and advice.
Such a service could be offered immediately after the introduction of the commercial product.
Conclusion
Portal dosimetry and especially in-treatment portal dosimetry is subject to commercial inter-
est by both vendors and radiotherapy departments across the world but especially in Europe.
In-treatment portal dosimetry will enable the identification of dose differences caused by sev-
eral different sources but especially patient specific differences in patient setup, and changes in
patient anatomy. To quoteMijnheer et al ”All treatments with curative intent should be verified
through in treatment dose measurements in combination with pre-treatment checks”. The in-
terest in portal dosimetry and new legislations in especially Europe has led to the licensing of
the current portal dosimetrymethods, and that novel time-resolved portal dosimetrymethods
have been patented in collaboration with a large medical company and might become com-
mercially available in the next few years. Especially the novel time-resolved portal dosimetry
can play an essential role in the in-treatment verification of highly dynamic treatments like
volumetric modulated arc therapy. While the methods are being implemented for large-scale
future use the adaptive strategies have to be developed as they have been developed up to now
based on image guidance, which should now be extended to dose guidance.
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